Advanced search
Publication Cover
Infection and Drug Resistance Volume 13, 2020 - Issue
Submit an article Journal homepage
151
Views
14
CrossRef citations to date
0
Altmetric
Review

Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?

Mena Al-Ani1 Department of Clinical Sciences, College of Medicine and the Immuno-Oncology Group, Sharjah Institute for Medical Research, University of Sharjah, Sharjah27272, United Arab Emirates
,
Noha Mousaad Elemam1 Department of Clinical Sciences, College of Medicine and the Immuno-Oncology Group, Sharjah Institute for Medical Research, University of Sharjah, Sharjah27272, United Arab EmiratesORCID Iconhttps://orcid.org/0000-0002-3586-6731
ORCID Icon,
Jennifer Elisabeth Hundt2 Lübeck Institute for Experimental Dermatology, University of Lübeck, Lübeck, Germany
&
Azzam A Maghazachi1 Department of Clinical Sciences, College of Medicine and the Immuno-Oncology Group, Sharjah Institute for Medical Research, University of Sharjah, Sharjah27272, United Arab EmiratesCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3310-678X
ORCID Icon
Pages 3243-3254 | Published online: 22 Sep 2020

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Gianmarco Abbadessa, Luigi Lavorgna, Francesca Trojsi, Cinzia Coppola & Simona Bonavita. (2021) Understanding and managing the impact of the Covid-19 pandemic and lockdown on patients with multiple sclerosis. Expert Review of Neurotherapeutics 21:7, pages 731-743.
Read now

Articles from other publishers (13)

Robert Sharkus, Richa Thakkar, Dennis L. Kolson & Cris S. Constantinescu. (2023) Dimethyl Fumarate as Potential Treatment for Alzheimer’s Disease: Rationale and Clinical Trial Design. Biomedicines 11:5, pages 1387.
Crossref
Parniyan Sadeghi, Parmida Sadat Pezeshki & Nima Rezaei. (2023) Coronavirus disease 2019 (COVID-19) in pediatric patients with autoimmune disorders. European Journal of Pediatrics 182:7, pages 2967-2988.
Crossref
Alireza Zafarani, Mohammad Hossein Razizadeh, Salar Pashangzadeh, Mohammad Reza Amirzargar, Mahsa Taghavi-Farahabadi & Mohammad Mahmoudi. (2023) Natural killer cells in COVID-19: from infection, to vaccination and therapy. Future Virology 18:3, pages 177-191.
Crossref
Marija Radmilo, Sanda Pavelin, Igor Vujović, Joško Šoda & Maja Rogić Vidaković. (2023) Confirmation of CD19+ B-Lymphocyte Depletion Prior to Intake of the Second Dose of Ocrelizumab in Multiple Sclerosis Patients. Biomedicines 11:2, pages 353.
Crossref
Radwa Mekky, Noha Elemam, Omar Eltahtawy, Yousra Zeinelabdeen & Rana Youness. (2022) Evaluating Risk: Benefit Ratio of Fat-Soluble Vitamin Supplementation to SARS-CoV-2-Infected Autoimmune and Cancer Patients: Do Vitamin–Drug Interactions Exist?. Life 12:10, pages 1654.
Crossref
Andrey M. Petrov, Marina V. Votintseva & Igor D. Stolyarov. (2022) Safety of pathogenetic therapy for multiple sclerosis during the COVID-19 pandemic. Annals of Clinical and Experimental Neurology 16:2, pages 70-77.
Crossref
Carmen Adella Sirbu, Raluca Ivan, Titus Mihai Vasile, Lucian George Eftimie & Daniel Octavian Costache. (2022) Cutaneous Adverse Reactions Associated with Monoclonal Antibodies Treatment in Multiple Sclerosis: Case Reports and Short Literature Review. Journal of Clinical Medicine 11:13, pages 3702.
Crossref
Noha M. Elemam, Sarah Hammoudeh, Laila Salameh, Bassam Mahboub, Habiba Alsafar, Iman M. Talaat, Peter Habib, Mehmood Siddiqui, Khalid Omar Hassan, Omar Yousef Al-Assaf, Jalal Taneera, Nabil Sulaiman, Rifat Hamoudi, Azzam A. Maghazachi, Qutayba Hamid & Maha Saber-Ayad. (2022) Identifying Immunological and Clinical Predictors of COVID-19 Severity and Sequelae by Mathematical Modeling. Frontiers in Immunology 13.
Crossref
Clara G. Chisari, Simona Toscano, Sebastiano Arena, Chiara Finocchiaro, Arturo Montineri & Francesco Patti. (2021) Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. BMC Neurology 21:1.
Crossref
E. V. Popova, M. I. Alexandrov, I. A. Trubnikova & S. R. Zeynalova. (2021) Clinical observation of the course of COVID-19 in patients with multiple sclerosis during ocrelizumab therapy: two clinical cases. Meditsinskiy sovet = Medical Council:10, pages 108-111.
Crossref
Michael J. Story. (2021) Essential sufficiency of zinc, ω-3 polyunsaturated fatty acids, vitamin D and magnesium for prevention and treatment of COVID-19, diabetes, cardiovascular diseases, lung diseases and cancer. Biochimie 187, pages 94-109.
Crossref
Maria C. Anagnostouli, Georgios Velonakis & Marinos C. Dalakas. (2021) Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate. Neurology - Neuroimmunology Neuroinflammation 8:4, pages e1017.
Crossref
Nabil A. Alhakamy, Osama A. A. Ahmed, Tarek S. Ibrahim, Hibah M. Aldawsari, Khalid Eljaaly, Usama A. Fahmy, Ahmed L. Alaofi, Filippo Caraci & Giuseppe Caruso. (2021) Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus. Pharmaceuticals 14:3, pages 178.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.